Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
Open Access
- 12 December 2007
- journal article
- review article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (1), 158-163
- https://doi.org/10.2967/jnumed.107.046185
Abstract
The Dock-and-Lock (DNL) method, which makes bioactive molecules with multivalency and multifunctionality, is a new approach to develop targeting molecules for improved cancer imaging and therapy. It involves the use of a pair of distinct protein domains involved in the natural association between cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) and A-kinase anchoring proteins (AKAPs). The dimerization and docking domain found in the regulatory subunit of PKA and the anchoring domain (AD) of an interactive AKAP are each attached to a biologic entity, and the resulting derivatives, when combined, readily form a stably tethered complex of a defined composition that fully retains the functions of the individual constituents. The DNL method has generated several trivalent, bispecific, binding proteins, each consisting of 2 identical Fab fragments linked site-specifically to a different Fab fragment. For example, 2 identical Fabs reacting with carcinoembryonic antigen (CEA) are bound to a Fab reacting with a hapten peptide that bears a diagnostic or therapeutic radionuclide. Using a 2-step, pretargeting method that separates the bivalent anti-CEA antibody targeting of tumor from the delivery of the radioactive peptide that is captured by the second Fab of the tri-Fab construct, an improved method of cancer imaging and therapy has been developed and shows very sensitive and specific targeting of CEA-expressing tumors for either diagnostic imaging, such as with immunoSPECT and immunoPET, or radioimmunotherapy. Improved therapeutic efficacy is shown with pretargeting in a pancreatic cancer xenograft model given a tri-Fab to a pancreatic cancer MUC1 and the hapten peptide labeled with 90Y.This publication has 32 references indexed in Scilit:
- Novel radiolabeled antibody conjugatesOncogene, 2007
- Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid TumorsClinical Cancer Research, 2006
- Targeted Therapy of Cancer: New Prospects for Antibodies and ImmunoconjugatesCA: A Cancer Journal for Clinicians, 2006
- Antibody Pretargeting Advances Cancer Radioimmunodetection and RadioimmunotherapyJournal of Clinical Oncology, 2006
- Advances in Radioimmunotherapy in the Age of Molecular Engineering and PretargetingCancer Investigation, 2006
- Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer XenograftClinical Cancer Research, 2005
- Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibodyNature Medicine, 2005
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting MethodsClinical Cancer Research, 2005
- Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibodyLeukemia, 2005
- Improved Targeting of Pancreatic CancerClinical Cancer Research, 2004